Breast Cancer
Opinion
The possibilities of pembrolizumab plus chemo in breast cancer treatment
Dr. Alan P. Lyss reviews studies of breast cancer patients receiving pembrolizumab in combination with chemotherapy.
From the Journals
Mammography does not reduce breast cancer deaths in women 75 and older
An observational study showed modest benefit for annual mammography in women aged 70-74 years, while women aged 75 years and older saw no benefit...
From the Journals
New study suggests milk could increase breast cancer risk
Drinking 1/4 to 1/3 cup of dairy milk per day was associated with a 30% increased risk of developing breast cancer.
From the Journals
Sharp climb in weight gain after breast cancer diagnosis
In the 2-year period after a breast cancer diagnosis, the proportion of women who were overweight or obese increased from 48% to 67%.
From the Journals
Abbreviated MRI bests digital breast tomosynthesis in finding cancer in dense breasts
Among women with dense breasts, abbreviated breast MRI identified more cases of invasive breast cancer, compared with digital breast tomosynthesis...
News
FDA approves neratinib in combination for metastatic HER2-positive breast cancer
Neratinib (NERLYNX) is approved for use in combination with capecitabine for adults with advanced or metastatic HER2-positive breast cancer who...
From the Journals
Medicaid expansion linked to more early cancer diagnoses
Patients in states that opted for Medicaid insurance expansion saw an increase in the rate of early diagnoses but similar wait times to treatment...
From the Journals
Irinotecan shows promise for triple-negative breast cancer
Irinotecan produced responses in patient-derived xenograft models of triple-negative breast cancer.
From the Journals
First robot for supermicrosurgery, used for lymphedema
The first trial of robot-assisted, high-precision supermicrosurgery in humans has shown that the technique was safe for treating breast cancer–...
From the Journals
Adding pembrolizumab to chemo doubled pCR rates in early-stage breast cancer
The doubling of pathologic complete response rates was seen in all three biomarker signatures studied.
From the Journals
Glaring gap in CV event reporting in pivotal cancer trials